Research identifies VPS25 gene as the genetic cause of a novel brain disorder — Evidence Review
Published in Genome Medicine, by researchers from King Faisal Specialist Hospital and Research Center, King Abdullah University of Science and Technology
Table of Contents
A newly published study has identified mutations in the VPS25 gene as the cause of a severe, previously unexplained neonatal brain disorder, providing long-awaited answers for affected families. Related research broadly supports the importance of rare genetic variants in neurological conditions, and this new finding adds to the growing list of genes implicated in early brain disorders, as highlighted by studies cataloguing genetic heterogeneity and shared mechanisms across neurological diseases.
- The identification of VPS25 as a disease gene aligns with prior large-scale studies showing that rare, recessive mutations account for a notable proportion of unexplained neurodevelopmental disorders, particularly in consanguineous families or those with multiple affected children 2 3 7.
- Recent reviews and genomic analyses emphasize that discovering new disease genes—especially those with high impact in childhood-onset brain conditions—remains a major avenue for improving diagnosis, genetic counseling, and our understanding of brain development 2 3 7.
- While studies of common genetic variants have revealed shared risk factors across psychiatric and some neurological disorders, the current finding reinforces the distinct impact of rare, highly penetrant mutations in severe pediatric conditions, complementing broader genetic architecture research 1 3 5.
Study Overview and Key Findings
Severe neonatal brain disorders that cause early seizures, developmental arrest, and early death have often remained unexplained, leaving families and clinicians with few answers and no guidance for future pregnancies. This study stands out by successfully pinpointing a specific genetic cause—mutations in VPS25—across multiple unrelated families and continents, using a combination of clinical genomics and cellular biology. The research demonstrates the value of international collaboration and large-scale genome programs, especially in regions with higher consanguinity, to uncover rare genetic diseases that would otherwise remain invisible. Importantly, the discovery not only clarifies the cause for affected families, but also offers a new target for diagnostic testing and genetic counseling in similar, previously unsolved cases.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | King Faisal Specialist Hospital and Research Center, King Abdullah University of Science and Technology |
| Journal Name | Genome Medicine |
| Authors | Ioannis Isaioglou, Lama AlAbdi, Muhammad Tehseen, Yossef Lopez de los Santos, Mansour Aldehaiman, Gloria Lopez-Madrigal, Norah Altuwaijri, Viviana Hermosilla Aguayo, Anna Pleyers, Maya Ayach, Ashraf Al-Amoudi, Jing Kai, Vlad-Stefan Raducanu, Bader Alhaddad, Edda Hofstätter, Amani Al-Amodi, Mais O. Hashem, Hessa S. Alsaif, Claudius Fazelnia, Firdous Abdulwahab, Amal Jaafar, Tarfa Alshidi, Rana Helaby, Adriana M. Montaño, Kara C. Klemp, Ellen Totten, Wesam Kurdi, Saly Eltohamy, Hadeel Abdollah E. Alrukban, Bashayer Alawam, Licia Selleri, Davor Lessel, Dimitrios Kapogiannis, Samir M. Hamdan, Stephen R. Braddock, Fowzan S. Alkuraya, Jasmeen S. Merzaban |
| Population | Newborns with brain abnormalities |
| Outcome | Identification of genetic cause of brain disorder |
| Results | VPS25 gene linked to a previously unknown brain disorder. |
Literature Review: Related Studies
To place these findings in context, we searched the Consensus research paper database, which includes over 200 million scholarly articles. The following search queries were used to identify relevant literature:
- VPS25 gene brain disorder connection
- unknown brain disorder genetic factors
- neurological disorders gene discovery implications
Below, we summarize key themes and findings from the related literature:
| Topic | Key Findings |
|---|---|
| How do rare genetic variants contribute to unexplained neurological disorders in newborns and children? | - Rare, recessive mutations account for a substantial proportion of severe, early-onset neurodevelopmental disorders, especially in consanguineous families 2 3. - Many neurological conditions remain genetically unresolved; systematic gene discovery efforts continue to expand the list of implicated genes 2 3 7. |
| What is the relationship between common and rare genetic variation in brain disorders? | - Common genetic variants underlie shared risk across several psychiatric and some neurological disorders, whereas rare, high-impact mutations tend to produce distinct, often severe phenotypes 1 3 5. - Genetic architecture differs between psychiatric and neurological disorders, with neurological conditions showing more genetic distinctness 1 5. |
| Why is large-scale genome sequencing critical for gene discovery in brain disorders? | - Whole-exome and genome sequencing in large and diverse cohorts, especially in multiplex or consanguineous families, has enabled the identification of dozens of novel disease genes 2 3 7. - Integrating genomic with clinical data accelerates the discovery and validation of causal genes for rare disorders 2 3 7. |
| What are the clinical implications of identifying new disease genes for neurological disorders? | - Genetic diagnosis can clarify recurrence risk, guide reproductive choices, and enable early prenatal or preimplantation genetic testing for affected families 2 3 7. - Expanding the catalog of disease genes improves diagnostic rates and facilitates genetic counseling in previously unsolved cases 2 3. |
How do rare genetic variants contribute to unexplained neurological disorders in newborns and children?
Recent studies have highlighted that rare, often recessive, genetic variants are a major cause of severe neurodevelopmental disorders that present in infancy or early childhood, particularly in populations with higher consanguinity. The new VPS25 study builds directly on this understanding—identifying a previously unknown cause of lethal neonatal encephalopathy—by leveraging international genomic resources and detailed clinical characterization. This approach follows a growing trend in the literature to systematically uncover rare, high-impact genetic causes in pediatric neurological disease.
- Whole-exome sequencing in consanguineous and multiplex families has identified many new disease genes for pediatric neurological disorders 2.
- Large-scale, tiered approaches integrating genomic and clinical data have enabled the identification of hundreds of candidate genes for developmental brain disorders 3.
- Many severe neonatal or infantile encephalopathies remain unexplained; systematic gene discovery is critical for addressing these clinical mysteries 2 3.
- The VPS25 study exemplifies how aggregating rare cases across continents can reveal new disease genes and phenotypes 2 3.
What is the relationship between common and rare genetic variation in brain disorders?
Research over the past decade has established that while common genetic variants can increase risk for a spectrum of psychiatric and some neurological disorders, rare, pathogenic mutations are frequently responsible for severe, early-onset, and often syndromic conditions. The current study's identification of a recessive, highly penetrant VPS25 mutation fits this model, highlighting the importance of rare variants in unexplained pediatric disorders, distinct from the polygenic risk seen in many adult-onset brain conditions.
- Psychiatric disorders share common variant risk factors, but neurological disorders (like those caused by VPS25 mutations) tend to be more genetically distinct 1.
- Rare, monogenic forms of brain disorders often present with severe, early-onset phenotypes, unlike the more subtle risk conferred by common variants 1 3 5.
- The clinical spectrum of developmental brain disorders often involves both rare and common genetic contributors, but highly penetrant mutations such as VPS25 are key in explaining severe familial cases 1 3.
- Understanding both rare and common variant contributions is necessary for a complete view of disease etiology 1 3 5.
Why is large-scale genome sequencing critical for gene discovery in brain disorders?
The integration of large-scale genomic sequencing, particularly in diverse and consanguineous populations, has revolutionized the discovery of new disease genes in neurology. The VPS25 study illustrates the impact of international genomic consortia and data sharing in uncovering ultra-rare disease mechanisms that would be invisible in single-center studies, reinforcing calls for continued expansion of genomic resources and international collaboration.
- Sequencing of prescreened, multiplex consanguineous families has led to the discovery of dozens of new recessive disease genes for neurological disorders 2.
- Cross-disorder and multilevel integration of genetic and clinical data increases yield and improves prioritization of candidate genes 3.
- Large, collaborative genome programs are essential to assemble enough cases for robust gene discovery in ultra-rare disorders 2 3 7.
- The approach used in the VPS25 study is a model for tackling the "long tail" of unsolved rare neurological diseases 2 3 7.
What are the clinical implications of identifying new disease genes for neurological disorders?
Finding the precise genetic cause of a rare brain disorder has immediate implications for affected families and healthcare providers. Accurate diagnosis enables informed reproductive decisions, targeted genetic counseling, and the possibility of early detection in future pregnancies. The new VPS25 finding is a clear example of how gene discovery can close the diagnostic gap and improve support for families facing devastating neonatal diseases.
- Genetic diagnosis provides answers for families, clarifies recurrence risk, and enables options like prenatal diagnosis and preimplantation genetic testing 2 3.
- Expanding the catalog of disease genes improves the diagnostic rate for unsolved neurological cases, benefiting both clinical management and research 2 3.
- Discoveries like VPS25 facilitate the development of more comprehensive genetic testing panels and may guide future therapeutic strategies 2 3 7.
- Early genetic diagnosis can help prevent repeated unexplained losses in families with inherited forms of brain disease 2 3.
Future Research Questions
Although the identification of VPS25 mutations as the cause of a novel neonatal brain disorder marks a significant advance, several critical questions remain. Future research will need to address gaps in understanding the full clinical spectrum, disease mechanism, and broader implications for diagnosis and therapy in neurogenetic disorders.
| Research Question | Relevance |
|---|---|
| What is the full clinical spectrum of VPS25-associated brain disorders? | Determining whether VPS25 mutations can cause a wider range of neurological phenotypes beyond those described in newborns could expand diagnostic criteria and inform prognosis for affected families 2 3. |
| How do VPS25 mutations disrupt neural development at the cellular and molecular level? | Understanding the precise biological mechanisms—such as alterations in vesicular trafficking and neuronal maintenance—will clarify how VPS25 dysfunction leads to brain damage and may reveal therapeutic targets 2 7. |
| Are there additional families worldwide with VPS25 mutations causing similar disorders? | Identifying more cases will help define the prevalence, phenotypic variability, and inheritance patterns of VPS25-related disorders, improving diagnostic yield and genetic counseling 2 3. |
| Can early genetic testing for VPS25 mutations enable interventions or improved outcomes? | Assessing the potential for prenatal or early postnatal interventions—or simply earlier diagnosis—could inform clinical management and family support, as is increasingly possible for other genetic brain disorders 2 3. |
| What is the broader role of the ESCRT-II complex in human brain development and disease? | Given that VPS25 is part of the ESCRT-II machinery, exploring whether other ESCRT genes are linked to similar or distinct neurological syndromes could reveal shared disease pathways and therapeutic opportunities 2 7. |